Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease

Inflamm Bowel Dis. 2020 Jan 6;26(2):e5. doi: 10.1093/ibd/izz286.

Authors

Christina M Bauer^{1

2}, Adam Younis³, Hans Herfarth^{1

2}, Edward L Barnes^{1

2}

Affiliations

¹ Division of Gastroenterology and Hepatology, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
² Multidisciplinary Center for Inflammatory Bowel Disease, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
³ Department of Internal Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.

PMID: 31750909
DOI: 10.1093/ibd/izz286

No abstract available

Keywords: Crohn's disease; adalimumab; antitumor necrosis factor; infliximab; loss of response.

Publication types

Letter
Comment

MeSH terms

Adalimumab
Crohn Disease*
Humans
Inflammatory Bowel Diseases*
Infliximab
Registries
Tumor Necrosis Factor-alpha

Substances

Tumor Necrosis Factor-alpha
Infliximab
Adalimumab